Kraig Biocraft Laboratories Issues a Letter to Shareholders on Recent Advancements and Potential Recombinant Spider Silk Deliveries in 2025

ANN ARBOR, Mich., June 03, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, issues a letter to shareholders.

Dear Shareholders,

We recently received inquiries from several of our shareholders. In preparing those responses, we realized that we should share the contents with the broader Kraig Labs community. Many had questions related to last week's announcement of the development of the new production strain and the potential for commercial deliveries in 2025.

The development of a new spider silk production transgenic has been a key part of our production roadmap since 2023 and a primary objective of our genetics team during the last 18 months. Our longstanding plans were to field a new strain of silkworm for our double hybrid production system in the Summer of 2025. To be frank, we were unsure whether we could meet that ambitious schedule. We were, therefore, ecstatic to announce that we created another world's first development on schedule. This and many of our other laboratory announcements are not only significant; they're foundational technology building blocks to our success.

Our current single hybrid system, utilizing BAM-1, has already shown massive improvement in robustness and silk production output. The newly announced strain is another significant improvement in our production, moving us a significant step closer to a more powerful double hybrid. The double hybrid model is designed to significantly improve our silk production rate; we expect by as much as 25+% per month, so this is something that we were very excited to share with our shareholders.

We are no longer experiencing the robustness challenges we faced with single-strain rearing. Before the rollout of the BAM-1 hybrid in 2024, our silkworms lacked the robustness to deal with the silkworm diseases and environmental stress that are frequently present in the field. In terms of robustness and disease tolerance, the BAM-1 appears to be on par with the Chinese commercial silk hybrid, which is the gold standard in that region for the production of mundane silk.

Now, this doesn't mean that we are invincible. Globally, between 10% to 30% of all silk production with robust double hybrids is lost due to a handful of diseases and adverse weather conditions. This is just a part of working with these living production systems. It is a fact that is reflected in global silk economics. Since rolling out the BAM-1, we have dealt with these routine challenges and have weathered these events with similar or identical effects as mundane silk producers utilizing the Chinese hybrid. Right now, the region's sericulture operators are in their rainy season, which is typically the worst time for silkworm rearing. Production of our BAM-1 strains and production of mundane silk producers utilizing Chinese hybrids are negatively impacted during this cycle. That is a normal part of silkworm rearing and is something that all silkworm producers encounter as a normal part of the business.

In the past, before we introduced BAM-1, the effects on our silkworms were significantly magnified and effectively stymied our growth. In short, there has been a revolution in our spider silk production technology over the past 14 months due to the introduction of BAM-1 and other improvements in the field and laboratory. As we meet our marks toward the initiation of the double hybrid, we anticipate our gains to accelerate further.

Regarding inventory calculation, our current inventory figures track finished raw reeled silk. In the first quarter of this year, we stockpiled several hundred kilograms of cocoon that are now waiting to be processed into finished silk. The reason inventory did not increase in our financial report was because that report tracked finished silk or material form. After considering these questions, and in light of the fact that we are moving from nominal inventory to larger scale production, we will expand the scope of our work-in-progress (WIP) material inventory to include recombinant spider silk cocoon that has been completed but not reeled. You can expect us to begin adding completed recombinant spider silk cocoon to our WIP to all future inventory balances.

We are 100% focused on the production of spider silk for commercial delivery. Over the last year, we've been able to move faster to deliver on that commitment. As a great example, we are in regular communication with three major Global brands that are standing by to receive their first shipments of materials. The first is an internationally renowned high-end luxury fashion brand that has already accepted a quote from Kraig Labs. The second is a world leader in high-end performance sportswear with an approved budget to buy silk from us. The third is one of the world's top 5 performance athletic equipment producers, looking for spider silk to integrate into their top-performing products. Supplying products to these three entities is the focus of our current production. Currently, we expect to begin deliveries to these customers in the second half of this year. That will be a significant milestone for Kraig Labs, our shareholders, and material science.

I believe the future for Kraig Labs and spider silk has never been brighter, and we thank you for your continued support.

Kim Thompson, CEO

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit .

For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel .

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to   

* For a description of our historical leadership in this technology, please follow this link

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

A photo accompanying this announcement is available at